Machina Medical

Executive Summary

Machina Medical is a San Francisco-based medical device company founded in 2018, focused on developing innovative hemostatic technologies to control severe bleeding. The company aims to bridge the critical time gap between traumatic injury and definitive medical care, with a mission to save lives and limbs through advanced wound care and hemorrhage control solutions. While still in an early stage (no disclosed funding rounds or commercial products), Machina Medical operates in a high-need market where rapid bleeding control is paramount in military, emergency, and surgical settings. Its proprietary platform could potentially offer superior efficacy and ease of use compared to existing hemostatic agents, targeting both civilian trauma and battlefield applications. Given the company's private status and limited public information, progress appears to be at the preclinical or early clinical stage. The addressable market is substantial, with growing demand for advanced hemostatic devices driven by rising trauma incidents and military modernization. However, execution risks include regulatory hurdles, manufacturing scalability, and competition from established players like HemCon and Celox. If successful, Machina Medical could become a key player in the hemorrhage control space, but conviction is tempered by the lack of disclosed development milestones or partnerships. The upcoming catalysts will be critical in validating the technology and advancing toward commercialization.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round Announcement70% success
• Q4 2026Completion of Preclinical Animal Studies60% success
• Q1 2027FDA 510(k) Submission for Lead Product40% success